Anke Vennegoor

DRS.

20092019
If you made any changes in Pure these will be visible here soon.

Research Output 2009 2019

  • 29 Article
  • 1 Research VU University Amsterdam, graduation VU University Amsterdam
Filter
Article
2019
2018

The fat embolism syndrome as a cause of paraplegia

Peters, S. T., Witvliet, M. J., Vennegoor, A., Ten Tusscher, B., Boden, B. & Bloemers, F. W., 2018, In : SAGE open medical case reports. 6, p. 2050313X18789318

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
2017

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

van Kempen, Z. L. E., Leurs, C. E., de Vries, A., Vennegoor, A., Rispens, T., Wattjes, M. P. & Killestein, J., 1 Sep 2017, In : European Journal of Neurology. 24, 9, p. 1196-1199 4 p.

Research output: Contribution to journalArticleAcademicpeer-review

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

van Schie, K. A., Kruithof, S., van Schouwenburg, P. A., Vennegoor, A., Killestein, J., Wolbink, G. & Rispens, T., 1 Mar 2017, In : Journal of Allergy and Clinical Immunology. 139, 3, p. 1035-1037.e6

Research output: Contribution to journalArticleAcademicpeer-review

2016

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients

Wattjes, M. P., Wijburg, M. T., Vennegoor, A., Witte, B. I., Roosendaal, S. D., Sanchez, E., Liu, Y., Jarnalo, C. O. M., Richert, N. D., Uitdehaag, B. M. J., Barkhof, F. & Killestein, J., Aug 2016, In : Multiple Sclerosis. 22, 9, p. 1174-1183

Research output: Contribution to journalArticleAcademicpeer-review

High cumulative JC virus seroconversion rate during long-term use of natalizumab

Vennegoor, A., van Rossum, J. A., Leurs, C., Wattjes, M. P., Rispens, T., Murk, J. L. A. N., Uitdehaag, B. M. J. & Killestein, J., Jun 2016, In : European Journal of Neurology. 23, 6, p. 1079-1085

Research output: Contribution to journalArticleAcademicpeer-review

MRI pattern in asymptomatic natalizumab-associated PML

Wattjes, M. P., Vennegoor, A., Steenwijk, M. D., Vos, M., Killestein, J., van Oosten, B. W., Mostert, J., Siepman, D. A., Moll, W., van Golde, A. E. L., Frequin, S. T. F. M., Richert, N. D. & Barkhof, F., 2015, In : Journal of Neurology, Neurosurgery and Psychiatry. 86, 7, p. 793-798

Research output: Contribution to journalArticleAcademicpeer-review

2014

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Wattjes, M. P., Vennegoor, A., Mostert, J., van Oosten, B. W., Barkhof, F. & Killestein, J., 2014, In : Journal of Neurology. 261, 6, p. 1139-1143

Research output: Contribution to journalArticleAcademicpeer-review

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

Killestein, J., Vennegoor, A., van Golde, A. E., Bourez, R. L., Wijlens, M. L. & Wattjes, M. P., 2014, In : Case Reports in Neurological Medicine. 2014, p. 307872 307872.

Research output: Contribution to journalArticleAcademicpeer-review

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients

van Rossum, J. A., Vennegoor, A., Balk, L., Uitdehaag, B. M. J., Polman, C. H. & Killestein, J., 2014, In : Multiple Sclerosis. 20, 1, p. 108-111

Research output: Contribution to journalArticleAcademicpeer-review

2013

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

Vennegoor, A., Rispens, T., Strijbis, E. M. M., Seewann, A., Uitdehaag, B. M. J., Balk, L. J., Barkhof, F., Polman, C. H., Wolbink, G. & Killestein, J., 2013, In : Multiple Sclerosis. 19, 5, p. 593-600

Research output: Contribution to journalArticleAcademicpeer-review

Drug interference in immunogenicity assays depends on valency

Rispens, T., Hart, M. H., Ooijevaar-de Heer, P., van Leeuwen, A., Vennegoor, A., Killestein, J., Wolbink, G. J. & van der Kleij, D., 2013, In : Journal of Pharmaceutical and Biomedical Analysis. 85, p. 179-185

Research output: Contribution to journalArticleAcademicpeer-review

2012

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

Rispens, T., Vennegoor, A., Wolbink, G. J., Polman, C. H. & Killestein, J., 2012, In : Multiple Sclerosis. 18, 6, p. 899-901

Research output: Contribution to journalArticleAcademicpeer-review

2011

Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients

Ketelslegers, I. A., Modderman, P. W., Vennegoor, A., Killestein, J., Hamann, D. & Hintzen, R. Q., 2011, In : Multiple Sclerosis. 17, 12, p. 1527-1530

Research output: Contribution to journalArticleAcademicpeer-review

Indolent Course of Progressive Multifocal Leukoencephalopathy During Natalizumab Treatment in Ms

Vennegoor, A., Wattjes, M. P., van Munster, E. T. L., Kriekaart, R. L., van Oosten, B. W., Barkhof, F., Killestein, J. & Polman, C. H., 2011, In : Neurology. 76, 6, p. 574-576

Research output: Contribution to journalArticleAcademicpeer-review

Indolent Course of Progressive Multifocal Leukoencephalopathy During Natalizumab Treatment in Ms Reply

Vennegoor, A., Wattjes, M., van Munster, E. T., Killestein, J. & Polman, C. H., 2011, In : Neurology. 77, 10, p. 1020-1020

Research output: Contribution to journalArticleAcademicpeer-review

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

Rispens, T., van Leeuwen, A., Vennegoor, A., Killestein, J., Aalberse, R. C., Wolbink, G. J. & Aarden, L. A., 2011, In : Analytical Biochemistry. 411, 2, p. 271-276

Research output: Contribution to journalArticleAcademicpeer-review

Reactie op ingezonden brief van drs. J.R. Schipper

Strijbis, E. M. M. & Vennegoor, A., 2011, In : Tijdschrift voor Neurologie & Neurochirurgie. 112, 5, p. 200

Research output: Contribution to journalArticleProfessional

2010

Natalizumab Drug Holiday in Multiple Sclerosis: Poorly Tolerated

Killestein, J., Vennegoor, A., Strijbis, E. M. M., Seewann, A. M., van Oosten, B. W., Uitdehaag, B. M. J. & Polman, C. H., 2010, In : Annals of Neurology. 68, 3, p. 392-395

Research output: Contribution to journalArticleAcademicpeer-review

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

van der Voort, L. F., Vennegoor, A., Visser, A., Knol, D. L., Uitdehaag, B. M. J., Barkhof, F., Oudejans, C. B. M., Polman, C. H. & Killestein, J., 2010, In : Neurology. 75, 14, p. 1228-1233

Research output: Contribution to journalArticleAcademicpeer-review

T lymphocytes impair P-glycoprotein function during neuroinflammation

Kooij, G., van Horssen, J., de Lange, E. C. M., Reijerkerk, A., van der Pol, S. M. A., Hof, B. V., Drexhage, J. A. R., Vennegoor, A., Killestein, J., Scheffer, G. L., Oerlemans, R., Scheper, R. J., van der Valk, P., Dijkstra, C. D. & de Vries, H. E., 2010, In : Journal of Autoimmunity. 34, 4, p. 416-425

Research output: Contribution to journalArticleAcademicpeer-review

2009

MxA mRNA level predicts relapses in a prospective cohort of early MS patients

van der Voort, L. F., Vennegoor, A., Visser, A., Knol, D. L., Uitdehaag, B. M. J., Barkhof, F., Oudejans, C. B. M., Polman, C. H. & Killestein, J., 2009, In : Multiple Sclerosis. 15, 9, p. S271-S272

Research output: Contribution to journalArticleAcademicpeer-review